Clinical trials: Primary Hypertension
Primary Open Angle Glaucoma
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with…
- Trial name
- NCT07235592
- Testing
- Microshunt XI
- Where
- 12 sites in Austria, Belgium and 6 more
- Volunteers
- 112 people
- Sponsor
- Santen SAS
Hypertension
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
- Trial name
- NCT00927537
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291), Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 2,052 people
- Sponsor
- Bayer
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT04820907
- Testing
- HCP1904-1, RLD2001-1
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Uncomplicated Hypertension
Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment
A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world…
- Trial name
- OptiZest (NCT06372470)
- Testing
- Zestril
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF
Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction
This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement.
- Conditions
- Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF, Hypertension, Systolic
- Trial name
- NCT07598760
- Testing
- Moderato Plus device with Cardiac Neuromodulation Therapy
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- BackBeat Medical Inc
Hypertension
Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
To evaluate the blood pressure lowering effect and safety of LCZ696 when given alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT01865188
- Testing
- LCZ696, Amlodipine, LCZ696 and amlodipine combination
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with…
- Trial name
- NCT00591773
- Testing
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone
- Where
- 46 sites in United States
- Volunteers
- 551 people
- Sponsor
- Takeda
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension, Dyslipidemia
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin…
- Trial name
- FIRST (NCT03156842)
- Testing
- Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Essential Hypertension
Olmesartan in Essential Hypertension
To test the efficacy and safety of olmesartan in patients with essential hypertension.
- Trial name
- NCT00185172
- Testing
- olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
- Where
- 8 sites in Austria, Germany and 6 more
- Volunteers
- 2,333 people
- Sponsor
- Sankyo Pharma Gmbh
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Essential Hypertension
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
- Trial name
- OLMETREAT (NCT00311155)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Where
- 79 sites in Austria, Belgium and 7 more
- Volunteers
- 694 people
- Sponsor
- Sankyo Pharma Gmbh
Hypertension
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
- Trial name
- NCT00246584
- Testing
- SPP100
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Hypertension
Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid…
- Trial name
- NCT01368185
- Volunteers
- 1,705 people
- Sponsor
- Organon and Co
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Essential Hypertension, Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group…
- Trial name
- FIESTA (NCT03338426)
- Testing
- Fimasartan 120mg, Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 133 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals